UPDATE: Goldman Sachs Upgrades FibroGen (FGEN) to Buy

July 20, 2015 7:34 AM EDT
Get Alerts FGEN Hot Sheet
Price: $21.56 +2.47%

Rating Summary:
    5 Buy, 8 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 4 | New: 24
Trade Now! 
Join SI Premium – FREE
(Updated - July 20, 2015 9:09 AM EDT)

Goldman Sachs upgraded FibroGen (NASDAQ: FGEN) from Neutral to Buy with a price target of $32 (unchanged). Analyst Terence Flynn said FibroGen's recent sell-off doesn't appear to be tied to fundamentals.

"Our 12-month price target remains at $32 and implies 36% upside potential. FGEN’s lead asset, Roxadustat (Roxa) is an oral drug in Phase 3 development for the treatment of anemia due to chronic kidney disease (CKD). We
believe this drug has the potential to penetrate and expand the $8.6bn injectable ESA market (mainly AMGN’s Epogen/Aranesp and JNJ’s Procrit/Eprex). Roxa is partnered with AZN (the United States and China) and Astellas (EU and Japan), offering independent validation of its novel mechanism of action (inhibition of HIF-PH)," said Flynn.

For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.

Shares of FibroGen closed at $23.21 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Hot Upgrades, Upgrades

Related Entities

Goldman Sachs